Literature DB >> 25867925

Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.

Gökhan Okan1, Adile Merve Baki2, Eda Yorulmaz3, Semra Doğru-Abbasoğlu2, Pervin Vural2.   

Abstract

BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disease associated with increase of some pro-inflammatory mediators. We wanted to investigate whether there is a relationship between psoriasis and visfatin, fetuin-A and pentraxin 3 (PTX3)-pro-inflammatory mediators implicated in the development of insulin resistance (IR), metabolic syndrome, and atherosclerosis.
METHODS: Visfatin, fetuin-A, and PTX3 concentrations were measured in 45 patients with plaque-type psoriasis and 45 healthy controls using enzyme-linked immunosorbent assay (ELISA).
RESULTS: Serum levels of visfatin, fetuin-A, and PTX3 in patients with psoriasis were found to be higher than in healthy controls (P = 0.002, P = 0.009, P < 0.001, respectively). Psoriasis area and severity index (PASI) score correlated significantly with visfatin and fetuin-A levels (P = 0.011, P = 0.040, respectively). There was a significant positive correlation between visfatin and fetuin-A (P < 0.001). PTX3 levels were correlated positively with homeostasis model assessment (HOMA-IR), insulin, triglyceride (TG), and very low density lipoprotein cholesterol (VLDL; P = 0.009, P = 0.007, P = 0.023, P = 0.024, respectively).
CONCLUSIONS: Increased serum visfatin, fetuin-A, and PTX3 levels, and the presence of positive correlation between visfatin, fetuin-A, and PASI score, probably reflect the inflammatory state and IR seen in psoriasis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  fetuin-A; inflammation; insulin resistance; pentraxin 3; psoriasis; visfatin

Mesh:

Substances:

Year:  2015        PMID: 25867925      PMCID: PMC6807040          DOI: 10.1002/jcla.21850

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  34 in total

Review 1.  Psoriasis.

Authors:  Frank O Nestle; Daniel H Kaplan; Jonathan Barker
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

2.  Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes.

Authors:  N Kanda; C S Hau; Y Tada; A Tatsuta; S Sato; S Watanabe
Journal:  Endocrinology       Date:  2011-06-14       Impact factor: 4.736

3.  Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules.

Authors:  Dirk Koczan; Reinhard Guthke; Hans-Jürgen Thiesen; Saleh M Ibrahim; Günther Kundt; Helga Krentz; Gerd Gross; Manfred Kunz
Journal:  Eur J Dermatol       Date:  2005 Jul-Aug       Impact factor: 3.328

Review 4.  Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.

Authors:  A Stofkova
Journal:  Endocr Regul       Date:  2010-01

5.  Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity.

Authors:  S A Ismail; S A Mohamed
Journal:  Br J Dermatol       Date:  2012-07-05       Impact factor: 9.302

6.  Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile.

Authors:  Michela Zanetti; Alessandra Bosutti; Clara Ferreira; Pierandrea Vinci; Gianni Biolo; Maurizio Fonda; Matteo Valente; Luigi Cattin; Gianfranco Guarnieri; Rocco Barazzoni
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

7.  Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.

Authors:  Tuva B Dahl; Arne Yndestad; Mona Skjelland; Erik Øie; Arve Dahl; Annika Michelsen; Jan K Damås; Siv H Tunheim; Thor Ueland; Camilla Smith; Bjørn Bendz; Serena Tonstad; Lars Gullestad; Stig S Frøland; Kirsten Krohg-Sørensen; David Russell; Pål Aukrust; Bente Halvorsen
Journal:  Circulation       Date:  2007-02-05       Impact factor: 29.690

8.  Psoriasis patients show signs of insulin resistance.

Authors:  S Boehncke; D Thaci; H Beschmann; R J Ludwig; H Ackermann; K Badenhoop; W-H Boehncke
Journal:  Br J Dermatol       Date:  2007-10-04       Impact factor: 9.302

Review 9.  Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies.

Authors:  April W Armstrong; Caitlin T Harskamp; Ehrin J Armstrong
Journal:  J Am Acad Dermatol       Date:  2013-01-27       Impact factor: 11.527

10.  Serological markers in psoriatic arthritis: promising tools.

Authors:  Roberta Ramonda; Valentina Modesti; Augusta Ortolan; Anna Scanu; Nicola Bassi; Francesca Oliviero; Leonardo Punzi
Journal:  Exp Biol Med (Maywood)       Date:  2013-10-21
View more
  11 in total

1.  Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C.

Authors:  Monica Salvi; Laura Macaluso; Cecilia Luci; Carlo Mattozzi; Giovanni Paolino; Yvonne Aprea; Stefano Calvieri; Antonio Giovanni Richetta
Journal:  World J Clin Cases       Date:  2016-02-16       Impact factor: 1.337

2.  Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis.

Authors:  Qian Zou; Jiawei Si; Yatao Guo; Jiayu Yu; Huijuan Shi
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

3.  Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Authors:  Gia Deyab; Ingrid Hokstad; Jon Elling Whist; Milada Cvancarova Småstuen; Stefan Agewall; Torstein Lyberg; Barbara Bottazzi; Pier Luigi Meroni; Roberto Leone; Gunnbjorg Hjeltnes; Ivana Hollan
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

Review 4.  Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.

Authors:  Stephen Chu-Sung Hu; Cheng-Che E Lan
Journal:  Int J Mol Sci       Date:  2017-10-21       Impact factor: 5.923

5.  Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: a systematic review and meta-analysis of case-control studies.

Authors:  Mazaher Ramezani; Elisa Zavattaro; Masoud Sadeghi
Journal:  Postepy Dermatol Alergol       Date:  2019-12-30       Impact factor: 1.837

6.  Is pentraxin 3 level an effective biomarker in disease activity in patients with rheumatoid arthritis?

Authors:  Ozlem Balbaloglu; Seda Sabah Ozcan
Journal:  Arch Med Sci       Date:  2019-07-11       Impact factor: 3.318

Review 7.  Role of Fetuin-A in the Pathogenesis of Psoriasis and Its Potential Clinical Applications.

Authors:  Endeshaw Chekol Abebe; Zelalem Tilahun Muche; Awgichew Behaile T/Mariam; Teklie Mengie Ayele; Melaku Mekonnen Agidew; Muluken Teshome Azezew; Edgeit Abebe Zewde; Tadesse Asmamaw Dejenie
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-04-08

8.  Fetuin-A mediates the difference in adipose tissue insulin resistance between young adult pakistani and norwegian patients with type 2 diabetes.

Authors:  Sindre Lee-Ødegård; Thor Ueland; Per M Thorsby; Pål Aukrust; Annika E Michelsen; Bente Halvorsen; Christian A Drevon; Kåre I Birkeland
Journal:  BMC Endocr Disord       Date:  2022-08-17       Impact factor: 3.263

9.  Angiopoietin-like protein 2 in psoriasis: a new linkage with metabolic syndrome.

Authors:  Mohamed Zaki Kenawy; Jehan Hasan Sabry; Essam Mohamed Akl; Noha A H Emam
Journal:  Postepy Dermatol Alergol       Date:  2020-03-09       Impact factor: 1.837

10.  Serum markers for asymptomatic atherosclerosis in Egyptian psoriatic patients: study controlled by Doppler estimation of carotid intima-media thickness.

Authors:  Hanan Hassan Sabry; Jehan Hassan Sabry; Aliaa El Husseiny Daifalla; Essam Mohamed Akl; Ahmed Mohamed Hamed; Ahmed Abd Allah Torky
Journal:  Vasc Health Risk Manag       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.